Literature DB >> 30043868

PORTAL PRESSURE DECREASE AFTER ESOPHAGOGASTRIC DEVASCULARIZATION AND SPLENECTOMY IN SCHISTOSOMIASIS: LONG-TERM VARICES BEHAVIOR, REBLEEDING RATE, AND ROLE OF ENDOSCOPIC TREATMENT.

Walter De Biase da Silva Neto1, Thiago Miranda Tredicci1, Fabricio Ferreira Coelho2, Fabio Ferrari Makdissi2, Paulo Herman2.   

Abstract

BACKGROUND: Schistosomiasis is an endemic health problem affecting about four million people. The hepatosplenic form of the disease is characterized by periportal hepatic fibrosis, pre-sinusoidal portal hypertension and splenomegaly. Liver function is preserved, being varices bleeding the main complication of the disease. The surgical treatment used in the majority of centers for the prevention of rebleeding is esophagogastric devascularization and splenectomy. Most authors reported better results with the association of surgical and postoperative endoscopic treatment.
OBJECTIVE: The aim of this study was to compare the intra operative portal pressure decrease and esophageal varices behavior and rebleeding rates in patients submitted to surgical and postoperative endoscopic treatment after long-term follow-up.
METHODS: A retrospective study of 36 patients with schistosomiasis with, at least, one previous bleeding from esophageal varices rupture submitted to esophagogastric devascularization and splenectomy, added to endoscopic varices postoperative treatment was performed. Patients were stratified according to the intra operative portal pressure decrease in two groups: reduction below and above 30%. Long-term varices presence, size and bleeding recurrence were evaluated.
RESULTS: Regarding varices behavior, no significant influence was observed in both groups of portal pressure fall. Regarding bleeding recurrence, despite three times more frequent in the group with lower portal pressure fall, no significant difference was observed. All patients were submitted to postoperative endoscopic treatment.
CONCLUSION: Esophageal varices banding, rather than portal pressure decrease, seems to be the main responsible factor for good results after combination of two therapies (surgery and endoscopy) for patients with portal hypertension due to schistosomiasis; further studies are necessary to confirm this hypothesis.

Entities:  

Mesh:

Year:  2018        PMID: 30043868     DOI: 10.1590/S0004-2803.201800000-30

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  4 in total

1.  Prognosis of endotherapy versus splenectomy and devascularization for variceal bleeding in patients with hepatitis B-related cirrhosis.

Authors:  Li Jiang; Hong-Shan Wei; Jia-Li Ma; Ling-Ling He; Ping Li
Journal:  Surg Endosc       Date:  2020-06-05       Impact factor: 4.584

2.  Splenectomy Combined with Endoscopic Variceal Ligation (EVL) versus EVL Alone for Secondary Prophylaxis of Variceal Bleeding in Hepatosplenic Schistosomiasis: A Retrospective Case-Control Study.

Authors:  Jolivet Auguste Rakotomalala; Chantelli Iamblaudiot Razafindrazoto; Nitah Harivony Randriamifidy; Behoavy Mahafaly Ralaizanaka; Sonny Maherison; Domoina Harivonjy Hasina Laingonirina; Mialitiana Rakotomaharo; Anjaramalala Sitraka Rasolonjatovo; Mamisoa Anicet Rakotovao; Andry Lalaina Rinà Rakotozafindrabe; Tovo Harimanana Rabenjanahary; Rija Fanantenantsoa; Soloniaina Hélio Razafimahefa; Rado Manitrala Ramanampamonjy
Journal:  Hepat Med       Date:  2022-05-18

Review 3.  Diagnosis and clinical management of hepatosplenic schistosomiasis: A scoping review of the literature.

Authors:  Francesca Tamarozzi; Veronica A Fittipaldo; Hans Martin Orth; Joachim Richter; Dora Buonfrate; Niccolò Riccardi; Federico G Gobbi
Journal:  PLoS Negl Trop Dis       Date:  2021-03-25

4.  Improvement of gut microbiome and intestinal permeability following splenectomy plus pericardial devascularization in hepatitis B virus-related cirrhotic portal hypertension.

Authors:  Yang Zhao; Rui Zhou; Ying Guo; Xi Chen; Aiyu Zhang; Jiayin Wang; Fanpu Ji; Bowen Qin; Jing Geng; Guangyao Kong; Zongfang Li
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.